Abstract:This study aimed to evaluate the prognostic value of circulating tumor cells (CTCs) and CTC clusters, termed circulating tumor microemboli (CTM), detected in patients with locally advanced rectal cancer (LARC) undergoing standard neoadjuvant chemoradiotherapy. From September 2014 to August 2015, the clinicopathological variables, such as gender, age, tumor location, depth of invasion, lymphatic invasion, distant metastasis, TNM stage, CTCs and CTM enumeration before chemoradiotherapy, of 42 newly acquired and histopathologically confirmed LARC patients were collected from the Fudan University Shanghai Cancer Center. All patients were followed up for survival until the end of December 2019. Statistical analysis focused on the associations between CTCs counts, CTM and clinicopathological variables. Overall survival (OS) and progression-free survival (PFS) among different prognostic factors were calculated using the Kaplan–Meier method, and the differences between the survival curves were compared by using the log-rank test. Factors of prognostic significance were investigated with the multivariate Cox regression analysis. CTCs and CTM were detected in 32% (13/42) and 57% (24/42) of patients, respectively. CTC-positive rate was positively correlated with the depth of invasion, lymphatic invasion, distant metastasis, TNM stage, and serum CEA level (P<0.05 for all). However, no significant difference was found between CTC-positive and other clinicopathological variables (P>0.05 for all), such as gender, age, tumor location, and tumor de-differentiation. CTCs counts gradually increased with the advancement of depth of invasion (P = 0.002), lymphatic invasion (P = 0.004), distant metastasis (P = 0.007), TNM stage (P = 0.001), serum CEA level (P = 0.001), and decreased tumor de-differentiation (P = 0.011). Furthermore, the Kaplan–Meier survival curves showed that patients with CTC-positive had a significantly unfavorable PFS (28 vs. 46 months, P = 0.001) and OS (36 vs. 50 months, P = 0.003). The multivariate Cox regression analyses revealed that the presence of CTCs before chemoradiotherapy was an independent factor for unfavorable PFS (hazard ratio (HR) 2.682, P = 0.017, 95% confidence interval (CI) 1.193–6.029) and OS (HR 2.790, P = 0.048, 95% CI 1.010–7.705) in LARC patients. This study provided an evidence that the presence of pretreatment CTCs may be valuable for predicting survival outcome, and CTCs was associated with unfavorable survival in LARC patients treated with neoadjuvant chemoradiotherapy.

Low CXCL11 expression is indicative of poor prognosis in rectal cancer patients undergoing preoperative chemoradiotherapy: a retrospective cohort study

Pre-operative radiochemotherapy of locally advanced rectal cancer.

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients

Clinical Factors of Post-Chemoradiotherapy As Valuable Indicators for Pathological Complete Response in Locally Advanced Rectal Cancer

Analysis of influencing factors of no/low response to preoperative concurrent chemoradiotherapy in locally advanced rectal cancer

Clinical Study on Locally Advanced Rectal Cancer Patients with Pathological Complete Response ;after Neoadjuvant Chemoradiotherapy

Treatment Response and Prognosis of Advanced Low Rectal Cancer after Neoadjuvant Radiotherapy and Chemotherapy

Predictors of Sensitivity to Preoperative Chemoradiotherapy of Rectal Adenocarcinoma

Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients

Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis

Rectal Cancer Patients with Downstaging after Neoadjuvant Chemoradiotherapy and Radical Resection Do Not Benefit from Adjuvant Chemotherapy

Prognostic Value of Circulating Tumor Cells and Circulating Tumor Microemboli in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

CCND1 As a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma.

The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.

Multivariate Analysis of Clinicopathologic Factors Correlated with Pathological Complete Response Following Preoperative Radiotherapy in Rectal Adenocarcinoma

Tumor Cell PD-L1 Predicts Poor Local Control for Rectal Cancer Patients Following Neoadjuvant Radiotherapy

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Pretreatment High Cholesterol and Low Neutrophils Predict Complete Pathological Response after Neoadjuvant Short‑course Radiotherapy Followed by Chemotherapy and Immunotherapy in Locally Advanced Rectal Cancer

Association of Tumor Differentiation and Prognosis in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiation Therapy